Acute myeloid leukemia resistant to venetoclax-based therapy: What does the future hold?

Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

(2022) Marina Konopleva et al.   CLINICAL CANCER RESEARCH

Strategies to Reduce the On‐Target Platelet Toxicity of Bcl‐x L Inhibitors: PROTACs, SNIPERs and Prodrug‐Based Approaches

(2022) Arvind Negi et al.   CHEMBIOCHEM

Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial

(2022) Huafeng Wang et al.   Lancet Haematology

Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia

(2022) Chong Chyn Chua et al.   Blood Advances

Venetoclax synergizes with Gilteritinib in FLT3 wildtype high-risk Acute Myeloid Leukemia by suppressing MCL-1

(2022) Maike Janssen et al.   BLOOD

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

(2021) Abhishek Maiti et al.   Blood Cancer Journal

Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML

(2021) Maximilian Stahl et al.   Blood Advances

Intact TP53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias

(2021) Rachel Thijssen et al.   BLOOD

Targeting AXL Kinase Sensitizes Leukemic Stem and Progenitor Cells to Venetoclax Treatment in Acute Myeloid Leukemia

(2021) Xiaojia Niu et al.   BLOOD

Development of TP53 mutations over the course of therapy for acute myeloid leukemia

(2021) Yasmin Alwash et al.   AMERICAN JOURNAL OF HEMATOLOGY

AML-162: Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Updated Analyses of a Phase 1b Study

(2021) Jessica K. Altman et al.   Clinical Lymphoma Myeloma & Leukemia

AML-196: The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results

(2021) David Sallman et al.   Clinical Lymphoma Myeloma & Leukemia

Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

(2021) Courtney D. DiNardo et al.   JOURNAL OF CLINICAL ONCOLOGY

Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial

(2021) Tapan M Kadia et al.   Lancet Haematology

Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

(2021) David A. Sallman et al.   BLOOD

Combined Blockade of CD47-Sirpa Interaction By 5F9 (Magrolimab) and Azacitidine/Venetoclax Therapy Facilitates Macrophage-Mediated Anti-Leukemia Efficacy in AML Pre-Clinical Models

(2021) Yannan Jia et al.   BLOOD

Quizartinib (Quiz) with Decitabine (DAC) and Venetoclax (VEN) Is Highly Active in Patients (pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) - RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance

(2021) Musa Yilmaz et al.   BLOOD

Preliminary Results By Age Group of Treatment with CPX-351 Plus Venetoclax in Adults with Newly Diagnosed AML: Subgroup Analysis of the V-FAST Phase 1b Master Trial

(2021) Vinod A. Pullarkat et al.   BLOOD

Phase II Study of Cladribine, Idarubicin, Cytarabine (CLIA) Plus Gilteritinib in Patients with FLT3 Mutated Acute Myeloid Leukemia (AML)

(2021) Tareq Abuasab et al.   BLOOD

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax Combined with Hypomethylating Agents

(2021) Daniel A. Pollyea et al.   BLOOD

A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study

(2021) Nicholas J. Short et al.   BLOOD

Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML

(2021) Naval Daver et al.   BLOOD

Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia

(2021) Evan M. Cherry et al.   Blood Advances

Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy

(2020) Naval G. Daver et al.   BLOOD

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

(2020) Courtney D. DiNardo et al.   BLOOD

Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Acute Myeloid Leukemia Patients

(2020) Shanshan Pei et al.   Cancer Discovery

Venetoclax plus LDAC for patients with untreated AML ineligible for intensive chemotherapy: phase 3 randomized placebo-controlled trial

(2020) Andrew Henry Wei et al.   BLOOD

Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models

(2020) Raghuveer Singh Mali et al.   HAEMATOLOGICA

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results.

(2020) David Andrew Sallman et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens

(2020) Abhishek Maiti et al.   HAEMATOLOGICA

Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy

(2020) Chong Chyn Chua et al.   JOURNAL OF CLINICAL ONCOLOGY

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

(2020) Courtney D. DiNardo et al.   NEW ENGLAND JOURNAL OF MEDICINE

How we use molecular minimal residual disease (MRD) testing in acute myeloid leukaemia (AML)

(2020) Richard Dillon et al.   BRITISH JOURNAL OF HAEMATOLOGY

Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells

(2020) Courtney L. Jones et al.   Cell Stem Cell

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

(2020) Courtney D DiNardo et al.   Lancet Haematology

TP-0903 is active in models of drug-resistant acute myeloid leukemia

(2020) Jae Yoon Jeon et al.   JCI Insight

The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML

(2019) Le Xuan Truong Nguyen et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

(2019) Andrew H. Wei et al.   JOURNAL OF CLINICAL ONCOLOGY

Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity

(2019) Kevin H. Lin et al.   Cell Metabolism

Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models

(2019) Lina Han et al.   HAEMATOLOGICA

Targeting mitochondrial structure sensitizes acute myeloid leukemia to Venetoclax treatment

(2019) Xufeng Chen et al.   Cancer Discovery

The TP53 Apoptotic Network is a Primary Mediator of Resistance to BCL2 inhibition in AML Cells

(2019) Tamilla Nechiporuk et al.   Cancer Discovery

Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-mutated Acute Myeloid Leukemia

(2019) Jun Ma et al.   CLINICAL CANCER RESEARCH

Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response

(2019) David Sharon et al.   Science Translational Medicine

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

(2018) Gerrit J. Schuurhuis et al.   BLOOD

Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018

(2018) Lorenzo Galluzzi et al.   CELL DEATH AND DIFFERENTIATION

A Novel MCL-1 Inhibitor Combined with Venetoclax Rescues Venetoclax Resistant Acute Myelogenous Leukemia

(2018) Haley E. Ramsey et al.   Cancer Discovery

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

(2018) Courtney D. DiNardo et al.   BLOOD

Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells

(2018) Courtney L. Jones et al.   CANCER CELL

Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia

(2018) Daniel A. Pollyea et al.   NATURE MEDICINE

Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells

(2016) X. Niu et al.   CLINICAL CANCER RESEARCH

Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia

(2015) Joshua F. Zeidner et al.   LEUKEMIA RESEARCH

Targeting MDM2-p53 Interaction for Cancer Therapy: Are We There Yet?

(2014) S. Nag et al.   CURRENT MEDICINAL CHEMISTRY

BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells

(2013) Eleni D. Lagadinou et al.   Cell Stem Cell